helicobacter pylori infection
Conditions
Interventions
control group :Rebeprazole enteric capsules (10mg bid) + amoxicillin (1000mg bid) + clarithromycin (500mg bid) + tequethine (260mg tid) for 14 days
Test Group A:Group A: tegerone (50mg bid) + amoxicillin (1000mg bid) + clarithromycin (500mg bid) + tequethine (260mg tid) for 14 days
Test Group B:Test Group B: Tigorol (50mg bid) + amoxicillin (1000mg tid) for 14 days
Sponsors
Civil Aviation General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Patients with positive urea breath test; (2) No previous Helicobacter pylori eradication treatment; (3) Age: 18~70 years old; (4) Was fully informed and agreed to participate in this study.
Exclusion criteria
Exclusion criteria: (1) 4 weeks before enrollment that may affect the results of the study, such as proton pump inhibitors, H2 receptor antagonists, bismuth or antibiotics; (2) Patients with gastrointestinal malignant tumors; (3) patients with upper gastrointestinal surgery; (4) Serious concomitant diseases that cannot tolerate treatment; (5) Patients with severe liver and kidney function damage, cardiovascular and cerebrovascular diseases, and mental illness; (6) Patients with allergies to the drugs used in this study; (7) Pregnant women or lactating women; (8) Patients with other medical conditions that may increase adverse treatment reactions (such as alcohol abuse).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HP eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse reaction rate;compliance; | — |
Countries
China
Contacts
Public ContactJianping Cheng
Civil Aviation General Hospital
Outcome results
None listed